Tomas Kiselak - 08 Jun 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Tomas Kiselak
Issuer symbol: VRDN
Transactions as of: 08 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 10 Jun 2022, 07:30:18 UTC
Previous filing: 16 Jun 2021
Next filing: 16 Jun 2023
SEC: View on sec.gov

Key filing fact

Tomas Kiselak filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 10 Jun 2022.

Key facts

This page summarizes Tomas Kiselak's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 10 Jun 2022, 07:30.

Change

Previous filing in this sequence was filed on 16 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 08 Jun 2022
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $12.31
Footnotes: F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.
F2	Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.